Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Extension of Indications for Lenvatinib

New indication concerns first-line treatment of advanced or unresectable hepatocellular carcinoma
04 Jul 2018
Gastrointestinal cancers;  Endocrine and neuroendocrine tumours;  Anticancer agents & Biologic therapy

On 28 June 2018, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product lenvatinib (Lenvima). 

The marketing authorisation holder for this medicinal product is Eisai Europe Ltd. 

The CHMP adopted a new indication and made a change to the existing indication. 

New indication concerns a monotherapy in the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy. 

The CHMP recommended a change for existing indication by specifying that lenvatinib is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine. 

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics, which will be published in the revised European public assessment report, and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission. 

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

Last update: 04 Jul 2018

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings